patents.google.com

IN2012DN01249A - - Google Patents

  • ️Fri May 15 2015
Download PDF

Info

Publication number
IN2012DN01249A
IN2012DN01249A IN1249DEN2012A IN2012DN01249A IN 2012DN01249 A IN2012DN01249 A IN 2012DN01249A IN 1249DEN2012 A IN1249DEN2012 A IN 1249DEN2012A IN 2012DN01249 A IN2012DN01249 A IN 2012DN01249A Authority
IN
India
Prior art keywords
group
alkyl group
haloalkyl
substituted
formula
Prior art date
2009-08-07
Application number
Inventor
Naoki Taka
Masayuki Ohmori
Kyoko Takami
Masayuki Matsushita
Tadakatsu Hayase
Ikumi Hyood
Masami Kochi
Hiroki Nishii
Hirosato Ebiike
Yoshito Nakanishi
Toshiyuki Mio
Lisha Wang
Weili Zhao
Original Assignee
Chugai Pharmaceutical Co Ltd
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2009-08-07
Filing date
2010-08-05
Publication date
2015-05-15
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43544423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN01249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
2010-08-05 Application filed by Chugai Pharmaceutical Co Ltd, Hoffmann La Roche filed Critical Chugai Pharmaceutical Co Ltd
2015-05-15 Publication of IN2012DN01249A publication Critical patent/IN2012DN01249A/en

Links

  • 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 3
  • 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 2
  • 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
  • 108091008794 FGF receptors Proteins 0.000 abstract 2
  • 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 abstract 2
  • 125000000217 alkyl group Chemical group 0.000 abstract 2
  • 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
  • 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
  • 206010028980 Neoplasm Diseases 0.000 abstract 1
  • 108091000080 Phosphotransferase Proteins 0.000 abstract 1
  • 201000011510 cancer Diseases 0.000 abstract 1
  • 150000001875 compounds Chemical class 0.000 abstract 1
  • 125000000623 heterocyclic group Chemical group 0.000 abstract 1
  • 102000020233 phosphotransferase Human genes 0.000 abstract 1
  • 150000003839 salts Chemical class 0.000 abstract 1

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0805—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a C6-10 aryl group; R1 and R2 independently represent H, OH, X, CN, NO2, a C1-4 haloalkyl group, a C1-6 alkyl group, or the like <R1 and R2 together form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group>; R3 represents H, a C1-5 alkyl group, a C6-10 aryl group, a C1-5 alkyl group, or a C1-4 haloalkyl group; and R4 represents H, X, a C1-3 alkyl group, a C1-4 haloalkyl group, OH, CN, NO2, or the like.)

IN1249DEN2012 2009-08-07 2010-08-05 IN2012DN01249A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009184822 2009-08-07
PCT/JP2010/063315 WO2011016528A1 (en) 2009-08-07 2010-08-05 Aminopyrazole derivative

Publications (1)

Publication Number Publication Date
IN2012DN01249A true IN2012DN01249A (en) 2015-05-15

Family

ID=43544423

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1249DEN2012 IN2012DN01249A (en) 2009-08-07 2010-08-05

Country Status (29)

Country Link
US (2) US8829199B2 (en)
EP (1) EP2471786B1 (en)
JP (2) JP5225470B2 (en)
KR (1) KR101529767B1 (en)
CN (1) CN102574836B (en)
AR (1) AR084370A1 (en)
AU (1) AU2010279930B2 (en)
BR (1) BR112012008094A2 (en)
CA (1) CA2770195C (en)
CL (1) CL2012000324A1 (en)
CY (1) CY1117142T1 (en)
DK (1) DK2471786T3 (en)
ES (1) ES2561659T3 (en)
HK (1) HK1170236A1 (en)
HR (1) HRP20151258T1 (en)
HU (1) HUE028584T2 (en)
IL (1) IL217912A (en)
IN (1) IN2012DN01249A (en)
MX (1) MX2012001653A (en)
MY (1) MY163531A (en)
PE (1) PE20120795A1 (en)
PH (1) PH12012500252A1 (en)
PL (1) PL2471786T3 (en)
PT (1) PT2471786E (en)
RU (1) RU2580543C9 (en)
SI (1) SI2471786T1 (en)
TW (1) TWI464160B (en)
WO (1) WO2011016528A1 (en)
ZA (1) ZA201200895B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101529767B1 (en) 2009-08-07 2015-06-17 추가이 세이야쿠 가부시키가이샤 Aminopyrazole derivative
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2817294B1 (en) * 2012-02-20 2017-12-27 Rhodia Operations Process for production of dfmb derivatives
ES2984771T3 (en) 2012-06-13 2024-10-31 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
PL2872491T3 (en) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
RU2673943C2 (en) * 2012-09-27 2018-12-03 Чугаи Сейяку Кабусики Кайся Fgfr3 fusion gene and pharmaceutical drug targeting same
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (en) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CN103224479B (en) * 2013-04-26 2014-10-15 温州大学 Synthetic method of 2-arylbenzofuran compounds
KR20160035003A (en) * 2013-07-31 2016-03-30 추가이 세이야쿠 가부시키가이샤 Pharmaceutical preparation comprising aminopyrazole derivative
RU2704112C2 (en) 2013-10-25 2019-10-24 Блюпринт Медсинс Корпорейшн Fibroblast growth factor receptor inhibitors
RU2653504C2 (en) * 2013-12-13 2018-05-10 Ф. Хоффманн-Ля Рош Аг Bruton's tyrosine kinase inhibitors
RU2648236C2 (en) * 2013-12-13 2018-03-23 Ф. Хоффманн-Ля Рош Аг Bruton's tyrosine kinase inhibitors
CA2929785C (en) * 2013-12-13 2018-02-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
DK3087986T3 (en) * 2013-12-27 2019-12-02 Chugai Pharmaceutical Co Ltd MUTANT FGFR GATEKEEPERGEN AND ACTIVE SUBSTANCE AIMED AT THE SAME
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
SG11201607772WA (en) 2014-03-31 2016-10-28 Debiopharm Int Sa Fgfr fusions
US9974785B2 (en) 2014-07-08 2018-05-22 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CA2956270C (en) 2014-08-18 2022-08-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE20171514A1 (en) 2015-02-20 2017-10-20 Incyte Corp BICYCLE HETEROCYCLES AS FGFR INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2016204261A1 (en) * 2015-06-17 2016-12-22 中外製薬株式会社 Aminopyrazole derivatives
CN108026588A (en) 2015-07-24 2018-05-11 德彪药业国际股份公司 FGFR is expressed and the sensitiveness to FGFR inhibitor
US10214515B2 (en) 2015-08-20 2019-02-26 Zhejiang Hisun Pharmaceutical Co., Ltd. Substituted pyrazoles as inhibitors of fibroblast growth factor receptor
CN107531679B (en) * 2016-03-18 2021-07-02 江苏恒瑞医药股份有限公司 Aromatic amide derivative, preparation method and medical application thereof
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
CR20200591A (en) 2018-05-04 2021-03-31 Incyte Corp Salts of an fgfr inhibitor
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
CN110950848B (en) * 2018-09-27 2024-03-26 徐诺药业 Synthesis and application of novel aminopyrazole derivative
CA3114883A1 (en) * 2018-10-02 2020-04-09 Disc Medicine, Inc. Matriptase 2 inhibitors and uses thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN110092791B (en) * 2019-05-17 2020-04-03 河南大学 5, 6-indolyldiodioxane derivatives, and preparation method and application thereof
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112358435B (en) * 2019-10-12 2023-01-10 中国医学科学院医药生物技术研究所 Substituted aromatic heterocyclic compound, preparation method, ULK1 inhibition and antitumor application
CN115835908A (en) 2019-10-14 2023-03-21 因赛特公司 Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505257A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Derivatives of FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3240059A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor
EP4450494A1 (en) * 2023-04-20 2024-10-23 Consejo Superior De Investigaciones Científicas Indole derivatives as histone deacetylase (hdac) inhibitors for the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ284157B6 (en) 1992-12-17 1998-08-12 Pfizer Inc. Pyrazole and pyrazolopyrimidine compounds per se and for treating diseases and pharmaceutical preparations based thereon
AU765030B2 (en) 1998-05-05 2003-09-04 F. Hoffmann-La Roche Ag Pyrazole derivatives as p-38 map kinase inhibitors
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
AU6762400A (en) * 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
JP2003050945A (en) 2001-08-06 2003-02-21 Takashi Hashimoto Interlocking type advertisement distribution system and operating method for advertisement distributing server
BR0213562A (en) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazoles and analogs and their use as protein kinase inhibitors
FR2831537B1 (en) 2001-10-26 2008-02-29 Aventis Pharma Sa NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF
FR2854159B1 (en) 2003-04-25 2008-01-11 Aventis Pharma Sa NOVEL INDOLE DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS KDR INHIBITORS
PT2298743E (en) * 2003-06-26 2012-12-04 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
EP1891048A1 (en) 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
FR2903406B1 (en) 2006-07-04 2012-08-10 Aventis Pharma Sa PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
BRPI0916233A2 (en) * 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag antiviral heterocyclic compounds
RU2011106357A (en) * 2008-07-23 2012-08-27 Ф.Хоффманн-Ля Рош Аг (Ch) HETEROCYCLIC ANTI-VIRAL COMPOUNDS
KR101529767B1 (en) 2009-08-07 2015-06-17 추가이 세이야쿠 가부시키가이샤 Aminopyrazole derivative

Also Published As

Publication number Publication date
AU2010279930B2 (en) 2014-09-04
US8829199B2 (en) 2014-09-09
AR084370A1 (en) 2013-05-15
US20140315856A1 (en) 2014-10-23
EP2471786A4 (en) 2013-03-27
CL2012000324A1 (en) 2012-09-14
BR112012008094A2 (en) 2020-08-18
JP5225470B2 (en) 2013-07-03
US20120208811A1 (en) 2012-08-16
CY1117142T1 (en) 2017-04-05
HUE028584T2 (en) 2016-12-28
ZA201200895B (en) 2012-11-28
DK2471786T3 (en) 2016-01-25
TWI464160B (en) 2014-12-11
JP5732081B2 (en) 2015-06-10
HK1170236A1 (en) 2013-02-22
IL217912A0 (en) 2012-03-29
KR20120085736A (en) 2012-08-01
AU2010279930A1 (en) 2012-03-08
KR101529767B1 (en) 2015-06-17
TW201116521A (en) 2011-05-16
PT2471786E (en) 2016-03-04
EP2471786B1 (en) 2015-11-04
CN102574836B (en) 2014-04-16
ES2561659T3 (en) 2016-02-29
MX2012001653A (en) 2012-06-19
RU2580543C9 (en) 2016-07-20
CA2770195C (en) 2015-10-13
WO2011016528A1 (en) 2011-02-10
HRP20151258T1 (en) 2016-02-26
EP2471786A1 (en) 2012-07-04
US9102692B2 (en) 2015-08-11
MY163531A (en) 2017-09-15
CA2770195A1 (en) 2011-02-10
RU2012108164A (en) 2013-09-20
SI2471786T1 (en) 2016-03-31
JPWO2011016528A1 (en) 2013-01-17
JP2013144679A (en) 2013-07-25
PH12012500252A1 (en) 2015-06-26
IL217912A (en) 2015-08-31
RU2580543C2 (en) 2016-04-10
CN102574836A (en) 2012-07-11
PL2471786T3 (en) 2016-04-29
PE20120795A1 (en) 2012-07-08

Similar Documents

Publication Publication Date Title
IN2012DN01249A (en) 2015-05-15
MX2011008176A (en) 2011-08-17 3, 3&#39; -spiroindolinone derivatives as anticancer agents.
MX2012009186A (en) 2012-08-23 Substituted pyrrolidine-2-carboxamides.
DE602007011902D1 (en) 2011-02-24 SPIROINDOLINON DERIVATIVES
MX2010004493A (en) 2010-06-11 Tropane compounds.
CR20120053A (en) 2012-05-21 JAK DE PIRAZOLOPIRIMIDINA INHIBITING COMPOUNDS AND METHODS
PH12012501711A1 (en) 2012-11-12 [5,6] heterocyclic compound
WO2013053983A8 (en) 2014-04-03 Protein kinase inhibitors
IN2012DN03129A (en) 2015-09-18
MX2012003982A (en) 2012-05-08 Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions.
WO2008114817A1 (en) 2008-09-25 Novel adenine compound
TW200801000A (en) 2008-01-01 Spiroindolinone derivatives
EP2380874A3 (en) 2011-12-07 Pleuromutilin derivatives for the treatment of diseases mediated by microbes
GB0412769D0 (en) 2004-07-07 Organic compounds
MY160882A (en) 2017-03-31 Biocidal composition and method
ZA201002139B (en) 2011-06-29 New compounds as adenosine a1 receptor antagonists
ATE404536T1 (en) 2008-08-15 SUBSTITUTED QUINOLINE DERIVATIVES AS INHIBITORS OF MITOTIC KINESIN
GB0501964D0 (en) 2005-03-09 Chemical compounds
EP2578617A4 (en) 2013-12-04 Polyamide compound
NZ595113A (en) 2013-02-22 Rosuvastatin and atorvastatin derivatives
ATE404554T1 (en) 2008-08-15 PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS
MX2009002606A (en) 2009-04-30 Arginine derivatives with np-i antagonistic activity.
WO2008017020A3 (en) 2008-07-17 Process for preparing proton pump inhibitors
WO2009006319A3 (en) 2009-03-12 Ammosamides as anticancer agents
WO2010115950A3 (en) 2011-10-13 Process for the preparation of pyrimidine derivatives